Diazoxide choline CR is a small molecule commercialized by Soleno Therapeutics, with a leading Phase III program in Prader-Willi Syndrome (PWS). According to Globaldata, it is involved in 12 clinical trials, of which 8 were completed, 1 is ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Diazoxide choline CR’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Diazoxide choline CR is expected to reach an annual total of $85 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Diazoxide choline CR Overview
Diazoxide choline controlled release (DCCR) is under development for the treatment of Prader-Willi syndrome, hypothalamic and SH2B1 deficiency obesity, hyperphagic obesity and Smith-Magenis syndrome. The drug candidate is formulated as a tablet and administered through oral route. It targets ATP sensitive inward rectifier potassium channel 11. It is a new chemical entity (NCE). The drug candidate was also under development for the treatment of hypertriglyceridemia and dyslipidemia.
Soleno Therapeutics Overview
Soleno Therapeutics (Soleno) formerly Capnia Inc, is a medical equipment company that designs, develops and commercializes novel therapeutic and diagnostic products. The company provides products such as serenz, cosense, and others. It offers serenz that is a hand-held device, which is used to obtain relief from the symptoms of allergies. Soleno provides cosense which is a portable device that is used to measure carbon monoxide in exhaled breath. The company offers various solutions to properly diagnose, monitor and care for children. It markets its products through its network of distributors. Soleno is headquartered in Redwood, California, the US.
The operating loss of the company was US$31.5 million in FY2021, compared to an operating loss of US$36.3 million in FY2020. The net loss of the company was US$30.9 million in FY2021, compared to a net loss of US$24.6 million in FY2020.
For a complete picture of Diazoxide choline CR’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.